Try our Advanced Search for more refined results
IN RE: ZOLOFT (SERTRALINE HYDROCHLORIDE) PRODUCTS LIABILITY LITIGATION
Case Number:
2:12-md-02342
Court:
Nature of Suit:
P.I.: Personal Inj. Prod. Liability
Multi Party Litigation:
Multi-district Litigation
Judge:
Firms
-
November 14, 2016
Consumers Want Zoloft Suits Out Of MDL And Back To Calif.
A number of consumers who want their suits alleging birth defects from Pfizer's Zoloft use during pregnancy told a Pennsylvania federal judge overseeing the multidistrict litigation that their suits should be sent back to California state court because their claims against a distributor have a shot at success there.
-
November 01, 2016
Pfizer Wants 15 Non-Calif. Plaintiffs Out Of Zoloft MDL
Pfizer Inc. asked a Pennsylvania federal judge on Monday to dismiss 15 plaintiffs who initially filed suit in California over alleged birth defects from Zoloft use during pregnancy from multidistrict litigation, saying their initial filing in California was illegitimate.
-
April 05, 2016
Pfizer Prevails In Zoloft Birth Defect MDL
A Pennsylvania federal judge granted summary judgment to Pfizer on Tuesday in over 300 cases claiming Zoloft caused babies' heart defects, effectively ending the drugmaker's sojourn in a major multidistrict litigation.
-
March 23, 2016
Pfizer Says Zoloft Defect Claims Still Suffer Lack Of Science
Pfizer Inc. has continued to fight parents targeting the drugmaker in multidistrict litigation over the alleged birth defect risks of its antidepressant Zoloft, arguing in Pennsylvania federal court that a recent submission by the parents purporting to be a recent epidemiology study is actually just a statement by the American Statistical Association.
-
March 11, 2016
Pfizer Fights Zoloft MDL Plaintiffs' New Expert Reports
Pfizer has continued to fight the latest efforts by parents of children born with heart defects to introduce expert reports into their suits over the alleged birth defect risks posed by its antidepressant Zoloft, telling the court presiding over the multidistrict litigation that the plaintiffs are effectively going back on their agreement.
-
March 04, 2016
Zoloft MDL Plaintiffs Fight To Keep Expert Reports
Parents of children born with heart defects have argued that they should be allowed to submit reports by their experts in the multidistrict litigation over the alleged birth defect risks of Pfizer's antidepressant Zoloft, saying those expert views are relevant to the drugmaker's pending summary judgment motion against their allegations.
-
March 01, 2016
Pfizer Tells Zoloft MDL Judge Case Fails Without Experts
Drugmaker Pfizer on Tuesday pushed for a Pennsylvania federal judge to toss allegations that its antidepressant drug Zoloft could cause birth defects, maintaining that the plaintiffs can't use individual diagnoses as a substitute for general expert testimony on causation of the birth defects to get the case to trial.
-
January 05, 2016
Zoloft MDL Judge Keeps Focus On Pfizer's Bid To Toss Claims
The Pennsylvania federal judge overseeing the multidistrict litigation over the alleged birth defect risks of Pfizer's antidepressant Zoloft on Monday reiterated her order to pause activity in the case besides the drugmaker's pending summary judgment motion, after it denounced the idea of having to challenge more expert reports.
-
December 04, 2015
Pfizer Seeks To Toss Zoloft Birth Defects MDL
Pfizer on Thursday asked a Pennsylvania federal judge to toss multidistrict litigation claiming antidepressant Zoloft could be linked to birth defects, the same day that the judge found expert testimony linking the drug to heart defects should be excluded since it relied on contradictory data.
-
December 03, 2015
Pfizer Wins Exclusion Of Zoloft Birth Defect Testimony
A Pennsylvania federal judge has found that the expert testimony used by plaintiffs in multidistrict litigation against Pfizer Inc. should be excluded, as the expert ignored contradictory data to conclude that the antidepressant Zoloft could be linked to birth defects.